mTOR inhibition beyond rapalogs

B. Markman; V. Serra; J. Tabernero

doi:10.1007/978-2-8178-0492-7

mTOR inhibition beyond rapalogs

B. Markman, V. Serra, J. Tabernero

Hudson Institute - Department of Molecular and Translational Science

Research output: Chapter in Book/Report/Conference proceeding › Chapter (Book) › Research › peer-review

Abstract

The development of therapeutic agents targeting the PI3K/Akt/mTOR pathway has been gaining momentum. The rapalogs are the most established group. New drug classes are emerging including those with single targets, those affecting multiple isoforms, and those seeking to inhibit multiple nodes within the signalling cascade. Data from clinical trials is contributing to the knowledge base of these novel compounds and is also posing further questions and challenges. Anti-cancer activity is being described but the overall response rates are lower than anticipated fuelling the need to better select patients and enrich target populations. Biomarkers are being utilized to achieve these aims and also to ensure desired pathway inhibition is occurring. Toxicities have been manageable and reversible in most cases. The next wave of studies is exploring PI3K/Akt/mTOR inhibitors administered in combination with hormones, cytotoxics, or other targeted therapies, amongst others. This chapter reviews the different classes of drugs in development as well as the pertinent findings from these clinical trials.

Original language	English
Title of host publication	mTOR Inhibition for Cancer Therapy
Subtitle of host publication	Past, Present and Future
Editors	Monica Mita, Alain Mita, Eric K. Rowinsky
Place of Publication	Paris France
Publisher	Springer
Pages	251 - 27
Number of pages	25
ISBN (Electronic)	978-2-8178-0492-7
ISBN (Print)	978-2-8178-0491-0
DOIs	https://doi.org/10.1007/978-2-8178-0492-7
Publication status	Published - 2016

Cite this

Markman, B., Serra, V., & Tabernero, J. (2016). mTOR inhibition beyond rapalogs. In M. Mita, A. Mita, & E. K. Rowinsky (Eds.), mTOR Inhibition for Cancer Therapy: Past, Present and Future (pp. 251 - 27). Springer. https://doi.org/10.1007/978-2-8178-0492-7

@inbook{3ec2691b2de241b3933e8cc7e47bfa77,

title = "mTOR inhibition beyond rapalogs",

abstract = "The development of therapeutic agents targeting the PI3K/Akt/mTOR pathway has been gaining momentum. The rapalogs are the most established group. New drug classes are emerging including those with single targets, those affecting multiple isoforms, and those seeking to inhibit multiple nodes within the signalling cascade. Data from clinical trials is contributing to the knowledge base of these novel compounds and is also posing further questions and challenges. Anti-cancer activity is being described but the overall response rates are lower than anticipated fuelling the need to better select patients and enrich target populations. Biomarkers are being utilized to achieve these aims and also to ensure desired pathway inhibition is occurring. Toxicities have been manageable and reversible in most cases. The next wave of studies is exploring PI3K/Akt/mTOR inhibitors administered in combination with hormones, cytotoxics, or other targeted therapies, amongst others. This chapter reviews the different classes of drugs in development as well as the pertinent findings from these clinical trials.",

author = "B. Markman and V. Serra and J. Tabernero",

year = "2016",

doi = "10.1007/978-2-8178-0492-7",

language = "English",

isbn = "978-2-8178-0491-0",

pages = "251 -- 27",

editor = "Monica Mita and Alain Mita and Rowinsky, {Eric K.}",

booktitle = "mTOR Inhibition for Cancer Therapy",

publisher = "Springer",

}

TY - CHAP

T1 - mTOR inhibition beyond rapalogs

AU - Markman, B.

AU - Serra, V.

AU - Tabernero, J.

PY - 2016

Y1 - 2016

N2 - The development of therapeutic agents targeting the PI3K/Akt/mTOR pathway has been gaining momentum. The rapalogs are the most established group. New drug classes are emerging including those with single targets, those affecting multiple isoforms, and those seeking to inhibit multiple nodes within the signalling cascade. Data from clinical trials is contributing to the knowledge base of these novel compounds and is also posing further questions and challenges. Anti-cancer activity is being described but the overall response rates are lower than anticipated fuelling the need to better select patients and enrich target populations. Biomarkers are being utilized to achieve these aims and also to ensure desired pathway inhibition is occurring. Toxicities have been manageable and reversible in most cases. The next wave of studies is exploring PI3K/Akt/mTOR inhibitors administered in combination with hormones, cytotoxics, or other targeted therapies, amongst others. This chapter reviews the different classes of drugs in development as well as the pertinent findings from these clinical trials.

AB - The development of therapeutic agents targeting the PI3K/Akt/mTOR pathway has been gaining momentum. The rapalogs are the most established group. New drug classes are emerging including those with single targets, those affecting multiple isoforms, and those seeking to inhibit multiple nodes within the signalling cascade. Data from clinical trials is contributing to the knowledge base of these novel compounds and is also posing further questions and challenges. Anti-cancer activity is being described but the overall response rates are lower than anticipated fuelling the need to better select patients and enrich target populations. Biomarkers are being utilized to achieve these aims and also to ensure desired pathway inhibition is occurring. Toxicities have been manageable and reversible in most cases. The next wave of studies is exploring PI3K/Akt/mTOR inhibitors administered in combination with hormones, cytotoxics, or other targeted therapies, amongst others. This chapter reviews the different classes of drugs in development as well as the pertinent findings from these clinical trials.

UR - http://link.springer.com/book/10.1007%2F978-2-8178-0492-7

U2 - 10.1007/978-2-8178-0492-7

DO - 10.1007/978-2-8178-0492-7

M3 - Chapter (Book)

SN - 978-2-8178-0491-0

SP - 251

EP - 227

BT - mTOR Inhibition for Cancer Therapy

A2 - Mita, Monica

A2 - Mita, Alain

A2 - Rowinsky, Eric K.

PB - Springer

CY - Paris France

ER -

Access to Document

10.1007/978-2-8178-0492-7

http://link.springer.com/book/10.1007%2F978-2-8178-0492-7